These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 29506673)

  • 1. Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma.
    Høgdall D; Lewinska M; Andersen JB
    Trends Cancer; 2018 Mar; 4(3):239-255. PubMed ID: 29506673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
    Rimassa L; Personeni N; Aghemo A; Lleo A
    J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma.
    Alnaggar M; Xu Y; Li J; He J; Chen J; Li M; Wu Q; Lin L; Liang Y; Wang X; Li J; Hu Y; Chen Y; Xu K; Wu Y; Yin Z
    J Immunother Cancer; 2019 Feb; 7(1):36. PubMed ID: 30736852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium.
    Gentilini A; Pastore M; Marra F; Raggi C
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30249019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.
    Loeuillard E; Yang J; Buckarma E; Wang J; Liu Y; Conboy C; Pavelko KD; Li Y; O'Brien D; Wang C; Graham RP; Smoot RL; Dong H; Ilyas S
    J Clin Invest; 2020 Oct; 130(10):5380-5396. PubMed ID: 32663198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions.
    Zhang G; Li J; Li G; Zhang J; Yang Z; Yang L; Jiang S; Wang J
    Clin Exp Med; 2024 Aug; 24(1):193. PubMed ID: 39141161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.
    Louis C; Edeline J; Coulouarn C
    Expert Opin Ther Targets; 2021 Feb; 25(2):153-162. PubMed ID: 33502260
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
    Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
    Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
    Zhang Q; Lou Y; Bai XL; Liang TB
    World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy.
    Nguyen CT; Caruso S; Maille P; Beaufrère A; Augustin J; Favre L; Pujals A; Boulagnon-Rombi C; Rhaiem R; Amaddeo G; di Tommaso L; Luciani A; Regnault H; Brustia R; Scatton O; Charlotte F; Brochériou I; Sommacale D; Soussan P; Leroy V; Laurent A; Le VK; Ta VT; Trinh HS; Tran TL; Gentien D; Rapinat A; Nault JC; Allaire M; Mulé S; Zucman-Rossi J; Pawlotsky JM; Tournigand C; Lafdil F; Paradis V; Calderaro J
    Clin Cancer Res; 2022 Feb; 28(3):540-551. PubMed ID: 34785581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of tumour microenvironment: a new vision for cholangiocarcinoma.
    Chen Z; Guo P; Xie X; Yu H; Wang Y; Chen G
    J Cell Mol Med; 2019 Jan; 23(1):59-69. PubMed ID: 30394682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma.
    Hua S; Gu X; Jin H; Zhang X; Liu Q; Yang J
    Biomed Pharmacother; 2024 Aug; 177():117080. PubMed ID: 38972151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for cholangiocarcinoma: a 2021 update.
    Charalampakis N; Papageorgiou G; Tsakatikas S; Fioretzaki R; Kole C; Kykalos S; Tolia M; Schizas D
    Immunotherapy; 2021 Sep; 13(13):1113-1134. PubMed ID: 34190581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 2021 FASEB Virtual Catalyst Conference on Cholangiocarcinoma: Molecular Drivers, Microenvironment, and Precision Medicine, April 7, 2021.
    Sirica AE
    FASEB J; 2021 Jul; 35(7):e21670. PubMed ID: 34169576
    [No Abstract]   [Full Text] [Related]  

  • 15. Cholangiocarcinoma - novel biological insights and therapeutic strategies.
    Ilyas SI; Affo S; Goyal L; Lamarca A; Sapisochin G; Yang JD; Gores GJ
    Nat Rev Clin Oncol; 2023 Jul; 20(7):470-486. PubMed ID: 37188899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy?
    Parks AL; McWhirter RM; Evason K; Kelley RK
    J Gastrointest Cancer; 2015 Jun; 46(2):161-5. PubMed ID: 25662892
    [No Abstract]   [Full Text] [Related]  

  • 17. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.
    Heits N; Heinze T; Bernsmeier A; Kerber J; Hauser C; Becker T; Kalthoff H; Egberts JH; Braun F
    BMC Cancer; 2016 May; 16():322. PubMed ID: 27206490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics.
    Zanetti M
    J Immunol; 2015 Mar; 194(5):2049-56. PubMed ID: 25710958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photothermal Depletion of Cancer-Associated Fibroblasts Normalizes Tumor Stiffness in Desmoplastic Cholangiocarcinoma.
    Nicolás-Boluda A; Vaquero J; Laurent G; Renault G; Bazzi R; Donnadieu E; Roux S; Fouassier L; Gazeau F
    ACS Nano; 2020 May; 14(5):5738-5753. PubMed ID: 32338871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in cholangiocarcinoma.
    Al-Rajabi R; Sun W
    Curr Opin Gastroenterol; 2021 Mar; 37(2):105-111. PubMed ID: 33507028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.